Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2018

01-01-2018 | Colorectal Cancer

Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study

Authors: Bo Young Oh, MD, PhD, Yoon Ah Park, MD, Jung Wook Huh, MD, PhD, Seong Hyeon Yun, MD, PhD, Hee Cheol Kim, MD, PhD, Ho-Kyung Chun, MD, PhD, Seok Hyung Kim, MD, PhD, Sang Yun Ha, MD, PhD, Woo Yong Lee, MD, PhD, Yong Beom Cho, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

Tumor budding is associated with adverse histology and is a predictor of lymph node metastasis. However, it remains unclear whether tumor budding is predictive of a poor prognosis for colon cancer patients. This study sought to investigate the prognostic significance of tumor budding in colon cancer.

Methods

This study evaluated 4196 colon cancer patients who underwent radical surgery from 2007 to 2013 at a single institution. The patients were categorized according to tumor-budding status. Adjustment was made for using propensity score-matched analysis, and both disease-free survival (DFS) and overall survival (OS) were compared between the groups.

Results

Among the 4196 patients, 2269 had low budding (< 5 buds), 1312 had intermediate budding (5–9 buds), and 615 had high budding (≥ 10 buds). High budding was associated with adverse histologic features such as elevated levels of preoperative carcinoembryonic antigen, advanced stage, poor histology, and the presence of lymphatic/vascular/perineural invasion. Before matching, DFS and OS decreased significantly with increasing tumor budding. After matching, the difference in survival between the low- and intermediate-budding groups disappeared. However, the OS and DFS rates for the high-budding group were significantly lower than for the other two groups. In the multivariate analysis of prognostic factors, high budding was an independent poor prognostic factor in DFS and OS, whereas tumor-budding positivity itself was not an independent prognostic factor.

Conclusion

Tumor-budding grade rather than tumor-budding positivity was an independent prognostic factor in colon cancer.
Appendix
Available only for authorised users
Literature
1.
Rogers AC, Gibbons D, Hanly AM, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27:156–62.CrossRefPubMed
2.
Imai. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi. 1954;45:30.
3.
Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers: lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539–43.CrossRefPubMed
4.
Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993;36:627–35.CrossRefPubMed
5.
Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127–32.CrossRefPubMed
6.
Shinto E, Jass JR, Tsuda H, et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum 2006;49:1422–30.CrossRefPubMed
7.
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299–311.CrossRefPubMed
8.
Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol. 2011;42:1833–40.CrossRefPubMed
9.
van Wyk HC, Park J, Roxburgh C, Horgan P, Foulis A, McMillan DC. The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: a systematic review. Cancer Treat Rev. 2015;41:151–9.CrossRefPubMed
10.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Hum Pathol. 2016;47:4–19.CrossRefPubMed
11.
Ohtsuki K, Koyama F, Tamura T, et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008;28:1831–6.PubMed
12.
Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33:134–41.CrossRefPubMed
13.
Syk E, Lenander C, Nilsson PJ, Rubio CA, Glimelius B. Tumour budding correlates with local recurrence of rectal cancer. Colorectal Dis. 2011;13:255–62.CrossRefPubMed
14.
van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ. The relationship between tumour budding, the tumour microenvironment, and survival in patients with primary operable colorectal cancer. Br J Cancer 2016;115:156–63.CrossRefPubMedPubMedCentral
15.
Kanazawa H, Mitomi H, Nishiyama Y, et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008;10:41–7.PubMed
16.
Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385–94.CrossRefPubMed
17.
Ha SS, Choi HJ, Park KJ, et al. Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma. Cancer Res Treat. 2005;37:177–82.CrossRefPubMedPubMedCentral
18.
Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:1597–602.CrossRefPubMed
19.
Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 2008;51:568–72.CrossRefPubMed
20.
Lai YH, Wu LC, Li PS, et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 2014;16:259–64.CrossRefPubMed
21.
Betge J, Kornprat P, Pollheimer MJ, et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012;19:3706–12.CrossRefPubMed
22.
Sy J, Fung CL, Dent OF, Chapuis PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis Colon Rectum 2010;53:301–7.CrossRefPubMed
23.
Rieger G, Koelzer VH, Dawson HE, et al. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Histopathology 2017;70:1044–51.CrossRefPubMed
24.
Horcic M, Koelzer VH, Karamitopoulou E, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2013;44:697–705.CrossRefPubMed
25.
Metadata
Title
Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study
Authors
Bo Young Oh, MD, PhD
Yoon Ah Park, MD
Jung Wook Huh, MD, PhD
Seong Hyeon Yun, MD, PhD
Hee Cheol Kim, MD, PhD
Ho-Kyung Chun, MD, PhD
Seok Hyung Kim, MD, PhD
Sang Yun Ha, MD, PhD
Woo Yong Lee, MD, PhD
Yong Beom Cho, MD, PhD
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6135-5

Other articles of this Issue 1/2018

Annals of Surgical Oncology 1/2018 Go to the issue

Gastrointestinal Oncology

Impact of Proximal Vascular Ligation on Survival of Patients with Colon Cancer

Health Services Research and Global Oncology

The Annals of Surgical Oncology: An Oncology Journal for Surgeons

Gastrointestinal Oncology

Short-Term Outcomes Following Minimally Invasive and Open Esophagectomy: A Population-Based Study from Finland and Sweden

Colorectal Cancer

Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Colorectal Cancer

The Relationship Between Clavien–Dindo Morbidity Classification and Oncologic Outcomes After Colorectal Cancer Resection

Bone and Soft Tissue Sarcomas

Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection